Buprenorphine Detoxification - BBDVI - 19

National Institutes of Health (NIH)

Status and phase: Completed; Phase 2

Conditions: Opioid-Related Disorders

Treatments: Drug: Buprenorphine

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00000237

NIDA-06969-19

R01-06969-19

Details and patient eligibility

About

The purpose of this study is to examine the long-term efficacy of alternate-day dosing schedules in promoting treatment compliance in the absence of confounding behavioral contingencies.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Please contact site for information.